Pharmacokinetics of Hydroxychloroquine and Its Clinical Implications in Chemoprophylaxis against Malaria Caused by Plasmodium vivax
Hyeong-Seok Lim,Jeong-Soo Im,Joo Youn Cho,Kyun-Seop Bae,Terry A. Klein,Joon Sup Yeom,Tae-Seon Kim,Jae-Seon Choi,In-Jin Jang,Jae-Won Park +9 more
Reads0
Chats0
TLDR
Hydroxychloroquine is an antimalarial drug used as chemoprophylaxis against malaria caused by Plasmodium vivax in the Republic of Korea Army (ROKA), and a significant cause of prophylactic failure among the individuals in ROKA was ascribed to plasma concentrations of HCQ lower than those predicted by the PK model.Abstract:
Hydroxychloroquine (HCQ) is an antimalarial drug used as chemoprophylaxis against malaria caused by Plasmodium vivax in the Republic of Korea Army (ROKA). In this study, we evaluated the pharmacokinetics (PK) of HCQ and its metabolites and the relationship between the PK of HCQ and the effect of treatment of HCQ on vivax malaria in South Koreans. Three PK studies of HCQ were conducted with 91 healthy subjects and patients with vivax malaria. Plasma concentrations were analyzed by noncompartmental and mixed-effect modeling approaches. A two-compartment model with first-order absorption best described the data. The clearance and the central and peripheral volumes of distribution were 15.5 liters/h, 733 liters, and 1,630 liters, respectively. We measured the plasma concentrations of HCQ in patients with prophylactic failure of HCQ and compared them with the prediction intervals of the simulated concentrations for HCQ from the final PK model built in this study. In 71% of the patients with prophylactic failure, the plasma concentrations of HCQ were below the lower bounds of the 95% prediction interval, while only 8% of them showed higher levels than the upper bounds of the 95% prediction interval. We report that a significant cause of prophylactic failure among the individuals in ROKA was ascribed to plasma concentrations of HCQ lower than those predicted by the PK model. However, prophylactic failure despite sufficient plasma concentrations of HCQ was confirmed in several individuals, warranting continued surveillance to monitor changes in the HCQ susceptibility of Plasmodium vivax in the Republic of Korea.read more
Citations
More filters
Journal ArticleDOI
Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review.
TL;DR: The COVID-19 pandemic represents the greatest global public health crisis of this generation and, potentially, since the pandemic influenza outbreak of 1918 and both the need and capability to produce high-quality evidence even in the middle of a pandemic.
Journal ArticleDOI
Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial.
Mayla Gabriela Silva Borba,Fernando Fonseca Almeida Val,Vanderson de Souza Sampaio,Márcia A. A. Alexandre,Gisely Cardoso de Melo,Marcelo A M Brito,Maria Paula Gomes Mourão,Jose Diego Brito-Sousa,Djane Clarys Baia-da-Silva,Marcus Vinitius de Farias Guerra,Ludhmila Abrahão Hajjar,R. Pinto,Antônio Alcirley da Silva Balieiro,Antonio G. Pacheco,James D. Santos,Felipe Gomes Naveca,Mariana Simão Xavier,André M. Siqueira,Alexandre Vargas Schwarzbold,Julio Croda,Julio Croda,Maurício Lacerda Nogueira,Gustavo Adolfo Sierra Romero,Quique Bassat,Cor Jesus Fernandes Fontes,Bernardino Cláudio de Albuquerque,Cláudio Tadeu Daniel-Ribeiro,Wuelton Marcelo Monteiro,Marcus Lacerda +28 more
TL;DR: The preliminary findings of this study suggest that the higher CQ dosage should not be recommended for critically ill patients with COVID-19 because of its potential safety hazards, especially when taken concurrently with azithromycin and oseltamivir.
Journal ArticleDOI
A phase I/II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme
Myrna R. Rosenfeld,Xiaobu Ye,Jeffrey G. Supko,Serena Desideri,Stuart A. Grossman,Steven Brem,Tom Mikkelson,Daniel I. C. Wang,Yunyoung C. Chang,Janice Hu,Quentin McAfee,Joy D. Fisher,Andrea B. Troxel,Shengfu Piao,Daniel F. Heitjan,Kay See Tan,Laura Pontiggia,Peter J. O'Dwyer,Lisa E. Davis,Ravi K. Amaravadi +19 more
TL;DR: Data establish that autophagy inhibition is achievable with HCQ, but dose-limiting toxicity prevented escalation to higher doses of HCQ.
Journal ArticleDOI
Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases
TL;DR: This review examines the pharmacokinetics, modes of action and therapeutic properties of the anti-malarial drugs, HCQ and CQ, in the treatment of systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) and related conditions, as well as osteoarthritis (OA).
Journal ArticleDOI
Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma
Reshma Rangwala,Robert D. Leone,Yunyoung C. Chang,Yunyoung C. Chang,Leslie A. Fecher,Lynn M. Schuchter,Amy Kramer,Kay See Tan,Daniel F. Heitjan,Glenda Rodgers,Maryann Gallagher,Shengfu Piao,Andrea B. Troxel,Tracey L. Evans,Angela DeMichele,Katherine L. Nathanson,Peter J. O'Dwyer,Jonathon Kaiser,Laura Pontiggia,Lisa E. Davis,Ravi K. Amaravadi +20 more
TL;DR: The combination of high-dose HCQ and dose-intense TMZ is safe and tolerable, and is associated with autophagy modulation in patients, indicating antitumor activity in melanoma patients is suggested.
References
More filters
Journal Article
[''R"--project for statistical computing].
TL;DR: An introduction to the R project for statistical computing (www.R-project.org) is presented to make the professional community aware of "R" as a potent and free software for graphical and statistical analysis of medical data.
Journal ArticleDOI
The economic and social burden of malaria
TL;DR: There are multiple channels by which malaria impedes development, including effects on fertility, population growth, saving and investment, worker productivity, absenteeism, premature mortality and medical costs.
Journal ArticleDOI
Inhibition by chloroquine of a novel haem polymerase enzyme activity in malaria trophozoites.
A. F. G. Slater,A. Cerami +1 more
TL;DR: The identification and characterization of a haem polymerase enzyme activity from extracts of Plasmodium fal-ciparum trophozoites are reported and show that this enzyme is inhibited by quinoline-containing drugs such as chloroquine and quinine, providing a possible explanation for the highly stage-specific anti-malarial properties of these drugs.
Journal ArticleDOI
Plasmodium vivax resistance to chloroquine
TL;DR: Two soldiers continued weekly prophylaxis with 300 mg chloroquine base on their return to Australia from Papua New Guinea but were not protected against Plasmodium vivax malaria, suggesting the emergence of strains of P v Vivax with a reduced susceptibility to chloroquines.
Journal ArticleDOI
Chloroquine Resistance in Plasmodium vivax
TL;DR: This minireview summarizes the present state of knowledge of CRPV as a scientific, clinical, and public health problem and examines the genesis of CQ therapy for P. vivax and the laboratory and clinical data underpinning the diagnosis.
Related Papers (5)
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Philippe Gautret,Jean-Christophe Lagier,Philippe Parola,Van Thuan Hoang,Line Meddeb,M. Mailhe,Barbara Doudier,Johan Courjon,Valérie Giordanengo,Vera Esteves Vieira,Hervé Tissot Dupont,Stéphane Honoré,Philippe Colson,Eric Chabrière,Bernard La Scola,Jean-Marc Rolain,Philippe Brouqui,Didier Raoult +17 more